Stocks News

LAST PRICE
143.1800
TODAY'S CHANGE (%)
Trending Down-1.6500 (-1.1393%)

Bid / Lots
121.0000/ 1
Ask / Lots
154.8600/ 1
Open / Previous Close
144.0000 / 144.8300
Day Range
Low 141.0100
High 146.4000
52 Week Range
Low 66.0300
High 161.0000
Volume
244,224
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism, from 12 hours ago by MT Newswires
  12 hours ago by MT Newswires
  Companies Mentioned: ASND
  11:33 AM EDT, 04/24/2024 (MT Newswires) -- Ascendis Pharma (ASND) said Wednesday that the UK's Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for Yorvipath as a parathyroid hormone, or PTH, replacement therap...
- United Kingdom's MHRA Approves YORVIPATH(R) (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism, from 15 hours ago by Dow Jones
  15 hours ago by Dow Jones
  Companies Mentioned: ASND
  
  United Kingdom's MHRA Approves YORVIPATH(R) (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism
  
  COPENHAGEN, Denmark, April 24, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the United Kingdom's Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for YORVIPATH(R) (palopegteriparatide; developed as TransCon(TM) PTH) in Great Britain as a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, and has also granted YORVIPATH orphan drug status. YORVIPATH is a prodrug of parathyroid hormone (PTH 1-34) administered once daily.
Apr 22, 2024
- DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 1:26PM ET on Monday Apr 22, 2024 by Dow Jones
  1:26PM ET on Monday Apr 22, 2024 by Dow Jones
  Companies Mentioned: ASND
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/ASND/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 22, 2024 13:26 ET (17:26 GMT)
Apr 19, 2024
- European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down, from 11:10AM ET on Friday Apr 19, 2024 by MT Newswires
  11:10AM ET on Friday Apr 19, 2024 by MT Newswires
  Companies Mentioned: SQNS, NCNA, AMRN, AUTL, OPRA, DAVA, BCYC, CALT, SLN, BPTS, BP, DBVT, ASND, CLLS, ADAP, EDAP
  11:10 AM EDT, 04/19/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending higher Friday morning, rising 0.46% to 1,330.20 on the S&P Europe Select ADR Index. Despite the gain, the index remains on pa...
Apr 18, 2024
- European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading, from 11:08AM ET on Thursday Apr 18, 2024 by MT Newswires
  11:08AM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: NTZ, VEON, SNY, TRIB, SQNS, AMRN, AUTL, OPRA, DAVA, BCYC, CRTO, TCBP, ASND, ADAP, BDRX, E
  11:08 AM EDT, 04/18/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were treading water in Thursday morning session, nudging 0.006% higher to 1,330.06 on the S&P Europe Select ADR Index. From continental Eur...

Yesterday
- Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours, from 6 hours ago by MT Newswires
  6 hours ago by MT Newswires
  Companies Mentioned: VKTX
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 8 hours ago by PR Newswire
  8 hours ago by PR Newswire
  Companies Mentioned: VKTX
- Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 8 hours ago by GlobeNewswire
  8 hours ago by GlobeNewswire
  Companies Mentioned: ITCI
Apr 23, 2024
- --Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating, from 10:58AM ET on Tuesday Apr 23, 2024 by MT Newswires
  10:58AM ET on Tuesday Apr 23, 2024 by MT Newswires
  Companies Mentioned: ITCI
Apr 22, 2024
- Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer, from 1:37PM ET on Monday Apr 22, 2024 by MT Newswires
  1:37PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: LEGN
- CARVYKTI(R) (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma, from 1:05PM ET on Monday Apr 22, 2024 by Business Wire
  1:05PM ET on Monday Apr 22, 2024 by Business Wire
  Companies Mentioned: LEGN
- --Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating, from 12:53PM ET on Monday Apr 22, 2024 by MT Newswires
  12:53PM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: ITCI
- --Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating, from 6:17AM ET on Monday Apr 22, 2024 by MT Newswires
  6:17AM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: ITCI
Apr 18, 2024
- Sector Update: Health Care Stocks Mixed Pre-Bell Thursday, from 9:12AM ET on Thursday Apr 18, 2024 by MT Newswires
  9:12AM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: IBB, ELV, XLV, CERE, BHVN
- Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study, from 8:35AM ET on Thursday Apr 18, 2024 by MT Newswires
  8:35AM ET on Thursday Apr 18, 2024 by MT Newswires
  Companies Mentioned: CERE

Ascendis Pharma A/S
NASDAQ:ASNDUnited States

Search Criteria

Yesterday

Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism, from 12 hours ago by MT Newswires

United Kingdom's MHRA Approves YORVIPATH(R) (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic Hypoparathyroidism, from 15 hours ago by Dow Jones

Apr 22, 2024

DJ Ascendis Pharma Is Maintained at Equal-Weight by Morgan Stanley, from 1:26PM ET on Monday Apr 22, 2024 by Dow Jones

Apr 19, 2024

European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down, from 11:10AM ET on Friday Apr 19, 2024 by MT Newswires

Apr 18, 2024

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading, from 11:08AM ET on Thursday Apr 18, 2024 by MT Newswires

Peers Headlines

Yesterday

Viking Therapeutics Q1 Loss Widens; Shares Fall After Hours, from 6 hours ago by MT Newswires

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update, from 8 hours ago by PR Newswire

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares, from 8 hours ago by GlobeNewswire

Apr 23, 2024

--Canaccord Genuity Raises Intra-Cellular Therapies' Price Target to $107 From $100, Maintains Buy Rating, from 10:58AM ET on Tuesday Apr 23, 2024 by MT Newswires

Apr 22, 2024

Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer, from 1:37PM ET on Monday Apr 22, 2024 by MT Newswires

CARVYKTI(R) (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma, from 1:05PM ET on Monday Apr 22, 2024 by Business Wire

--Needham & Co Adjusts Intra-Cellular Therapies Price Target to $90 From $82, Maintains Buy Rating, from 12:53PM ET on Monday Apr 22, 2024 by MT Newswires

--Mizuho Raises Price Target on Intra-Cellular Therapies to $96 From $82, Keeps Buy Rating, from 6:17AM ET on Monday Apr 22, 2024 by MT Newswires

Apr 18, 2024

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday, from 9:12AM ET on Thursday Apr 18, 2024 by MT Newswires

Cerevel Therapeutics' Potential Parkinson's Treatment Meets Primary Endpoint in Phase 3 Study, from 8:35AM ET on Thursday Apr 18, 2024 by MT Newswires